姜兆磊 梅舉 湯敏 馬南 張俊文 丁芳寶 劉浩 尹航
臨床研究
MIDCAB術(shù)治療心肌橋與非心肌橋性左前降支病變的臨床效果分析
姜兆磊 梅舉 湯敏 馬南 張俊文 丁芳寶 劉浩 尹航
目的 比較微創(chuàng)直視下冠狀動(dòng)脈旁路移植術(shù)(MIDCAB)治療心肌橋與非心肌橋性左前降支(LAD)病變的臨床效果。方法 2006年5月至2013年5月,37例冠心病患者在我院行MIDCAB手術(shù),其中男性29例,女性8例,年齡48~76(62.9±6.8)歲。術(shù)前冠心病造影診斷:心肌橋致LAD重度狹窄12例(心肌橋組),非心肌橋性LAD閉塞或LAD重度狹窄25例(非心肌橋組)。37例患者均經(jīng)左胸前側(cè)第4或第5肋間6 cm左右的小切口,非體外循環(huán)下完成LIMA-LAD吻合。結(jié)果 全組37例MIDCAB手術(shù)均順利完成,無(wú)術(shù)中轉(zhuǎn)為正中開(kāi)胸手術(shù),手術(shù)時(shí)間為117~143 min,圍術(shù)期均未輸血。術(shù)后呼吸機(jī)輔助通氣時(shí)間為4~16 h,ICU停留時(shí)間為22~45 h,術(shù)后住院時(shí)間為6~10 d,全部患者術(shù)后無(wú)急性心梗和腦卒中等嚴(yán)重并發(fā)癥及術(shù)后死亡,心肌橋組與非心肌橋組無(wú)明顯差異(P>0.05)。術(shù)后隨訪3~87(27.59±19.15)個(gè)月,所有患者均做多層CT檢查,LIMA-LAD吻合口通暢率為100%,全部患者沒(méi)有心絞痛癥狀。結(jié)論 MIDCAB治療心肌橋與非心肌橋性LAD病變可取得相同的優(yōu)良效果。
冠狀動(dòng)脈旁路移植術(shù);微創(chuàng)手術(shù);心肌橋
心肌橋(myocardial bridge,MB)是一種先天性冠狀動(dòng)脈變異,當(dāng)冠狀動(dòng)脈及其分支的某節(jié)段走行于心肌纖維之間時(shí),這段覆蓋于冠脈之上的心肌就稱之為MB。文獻(xiàn)報(bào)道,通過(guò)CTA、尸檢及冠脈造影等技術(shù),MB的檢出率為0.5%~58.0%[1-3]。大部分MB不引起臨床癥狀,但覆蓋于冠狀動(dòng)脈左前降支(LAD)中段的嚴(yán)重MB,可壓迫冠脈,引起冠狀動(dòng)脈粥樣硬化、冠脈痙攣、心肌梗死、心律失常以及心源性猝死等危害[4-6],因此,對(duì)此類MB則需要治療。我們應(yīng)用微創(chuàng)直視下冠狀動(dòng)脈旁路移植(minimally invasive direct coronary artery bypass,MIDCAB)技術(shù)治療12例MB致LAD重度狹窄患者,并與同期25例非MB性單純LAD病變的手術(shù)結(jié)果進(jìn)行比較?,F(xiàn)將我們采用MIDCAB術(shù)治療心肌橋的臨床結(jié)果作如下報(bào)道。
1.1 臨床資料與分組 2006年5月至2013年5月,37例單支LAD病變患者在我院行MIDCAB手術(shù),其中男性 29例,女性 8例,年齡 48~76(62.9±6.8)歲。所有患者均有典型的心絞痛發(fā)作癥狀,心肌橋患者心絞痛發(fā)作時(shí)心電圖均有明顯的缺血性改變。術(shù)前冠心病造影診斷:LAD心肌橋致其重度狹窄12例(心肌橋組),非心肌橋25例為L(zhǎng)AD閉塞6例、LAD長(zhǎng)節(jié)段重度狹窄7例和LAD起始部重度狹窄12例(非心肌橋組)。造影顯示LIMA均無(wú)病變。37例患者中合并高血壓26例、高脂血癥24例、糖尿病17例、腎功能不全3例,左室射血分?jǐn)?shù)為42%~66%。兩組患者術(shù)前資料見(jiàn)表1。
1.2 手術(shù)方法 全組均行全身麻醉、雙腔氣管插管、右側(cè)單肺通氣,體表放置體外除顫電極。左胸墊高30°,經(jīng)左胸前側(cè)第4或第5肋間做6 cm左右的小切口,借助于專用撐開(kāi)器,應(yīng)用長(zhǎng)柄鈦夾鉗、電刀,直視下獲取帶蒂的LIMA,上至第1肋,下至第5肋。所有患者LIMA獲取過(guò)程中顯露清晰,LIMA質(zhì)量均良好,LIMA長(zhǎng)度、直徑、血流量均滿意。完成LIMA取材后,換一小撐開(kāi)器,經(jīng)原胸壁切口縱行切開(kāi)心包并懸吊之,顯露靶血管LAD,在非體外循環(huán)下,借助于心臟固定器,切開(kāi)冠狀動(dòng)脈靶血管,內(nèi)置血液分流管,應(yīng)用7-0聚丙烯線完成LIMA-LAD吻合。術(shù)后常規(guī)應(yīng)用阿司匹林(長(zhǎng)期服用)和玻力維(6個(gè)月),并根據(jù)病情服用β受體阻滯劑、ACEI及降糖、降血脂類藥物。術(shù)后1、3、5年時(shí)做多層CT檢查,了解橋血管通暢情況。
1.3 統(tǒng)計(jì)學(xué)方法 運(yùn)用SPSS 18.0軟件進(jìn)行數(shù)據(jù)的統(tǒng)計(jì)學(xué)分析。計(jì)量數(shù)據(jù)以±s表示,兩組之間比較采用t檢驗(yàn);計(jì)數(shù)資料以例數(shù)表示,兩組之間比較采用χ2檢驗(yàn)。P<0.05表明差異有統(tǒng)計(jì)學(xué)意義。
全組37例MIDCAB手術(shù)均順利完成,無(wú)術(shù)中轉(zhuǎn)為正中開(kāi)胸手術(shù)。獲取LIMA時(shí)間為38~53 min,手術(shù)時(shí)間為117~143 min,出血量均少于100 ml,圍術(shù)期均未輸血,兩組間差異無(wú)統(tǒng)計(jì)學(xué)意義(P>0.05)。術(shù)后呼吸機(jī)輔助通氣時(shí)間4~16 h,ICU停留時(shí)間 22~45 h,術(shù)后住院時(shí)間為 6~10 d,全部患者術(shù)后無(wú)急性心梗和腦卒中等嚴(yán)重并發(fā)癥及術(shù)后死亡,兩組間差異無(wú)統(tǒng)計(jì)學(xué)意義(P>0.05)。見(jiàn)表2。術(shù)后隨訪 3~87(27.59±19.15)個(gè)月,所有患者均于術(shù)后1、3、5年時(shí)進(jìn)行多層CT檢查,全部患者LIMALAD吻合口通暢(100%),兩組間通暢率比較差異無(wú)統(tǒng)計(jì)學(xué)意義(P>0.05)。1例心肌橋患者術(shù)后2個(gè)月內(nèi)偶有胸悶癥狀,服用倍他樂(lè)克3個(gè)月后癥狀消失。其余患者均沒(méi)有心絞痛癥狀,生活、活動(dòng)均正常,心電圖無(wú)心肌缺血改變,心臟彩超顯示心功能良好。
心肌橋在臨床上并不少見(jiàn),尤其是隨著現(xiàn)代醫(yī)學(xué)檢查手段的提高,通過(guò)CT或冠脈造影對(duì)明確診斷并不困難。但是,要診斷心肌橋?qū)诿}壓迫的嚴(yán)重程度,則只能通過(guò)冠脈造影來(lái)評(píng)價(jià)[1,7,8],而且心肌橋壓迫冠脈的部位和壓迫的長(zhǎng)度也能得到評(píng)估[9,10]。心肌橋者有無(wú)癥狀,取決于其對(duì)冠狀動(dòng)脈壓迫的部位、深度、長(zhǎng)度,以及患者年齡等。大部分心肌橋者,尤其青少年,因心肌橋肌肉薄、短,對(duì)冠狀動(dòng)脈壓迫不明顯,沒(méi)有任何癥狀;少部分患者因?yàn)樾募驂浩仍谇敖抵е卸危募蚣∪夂?、長(zhǎng),對(duì)冠狀動(dòng)脈壓迫較深,因而出現(xiàn)心肌缺血樣癥狀十分明顯。心肌橋?qū)е滦募∪毖淖冎饕怯捎谛募蚴湛s直接壓迫冠狀動(dòng)脈而造成的,而在心臟舒張期,由于心肌橋得不到充分的舒張而影響了冠脈的擴(kuò)張,導(dǎo)致其供血不足[4,11,12]。但對(duì)于年齡大的心肌橋患者,長(zhǎng)期的心肌橋壓迫以及冠脈內(nèi)血流動(dòng)力學(xué)的改變,導(dǎo)致心肌橋近端的冠脈內(nèi)膜異常,進(jìn)而發(fā)展演變?yōu)橹鄻佑不瘶硬∽?,冠脈管腔狹窄,發(fā)生心肌缺血癥狀[4,13]。
表1 兩組患者術(shù)前臨床資料[(±s),例數(shù)及百分率(%)]
表1 兩組患者術(shù)前臨床資料[(±s),例數(shù)及百分率(%)]
組別 例數(shù) 年齡(歲) 男/女 術(shù)前LVEF(%) 高血壓 高脂血癥 糖尿病 腎功能不全心肌橋組 12 62.33±7.18 9/3 55.83±5.31 8(66.7) 7(58.3) 6(40.0) 1(8.3)非心肌橋組 25 63.12±6.69 20/5 52.48±6.60 18(72.0) 17(68.0) 11(44.0) 2(8.0)t值(χ2值) -0.327 0.000 1.535 0.000 0.044 0.061 0.000 P值 0.745 1.000 0.134 1.000 0.835 0.804 1.000
表2 術(shù)后早期結(jié)果(±s)
表2 術(shù)后早期結(jié)果(±s)
組別 例數(shù) 獲取LIMA時(shí)間(min)術(shù)后住院時(shí)間(d)心肌橋組 12 43.42±3.63 127.58±7.14 75.50±10.60 8.17±2.73 29.33±5.35 7.67±1.23非心肌橋組 25 45.32±4.20 130.24±7.13 80.12±9.61 9.04±2.97 32.36±6.91 8.00±1.26 t值 -1.345 -1.061 -1.325 -0.860 -1.334 -0.759 P值 0.187 0.296 0.194 0.396 0.191 0.453手術(shù)時(shí)間(min)術(shù)中出血量(ml)呼吸機(jī)輔助通氣時(shí)間(h)術(shù)后ICU住院時(shí)間(h)
心肌橋癥狀輕者可通過(guò)服用β受體阻斷劑、鈣拮抗劑,降低MB收縮力、減慢心率、延長(zhǎng)舒張期而得到治療[14,15];心肌橋?qū)е鹿诿}狹窄程度超過(guò)75%以上且癥狀嚴(yán)重的患者,藥物治療多無(wú)效,這時(shí)可選用冠脈支架治療或外科手術(shù)治療。文獻(xiàn)報(bào)道,支架治療心肌橋可直接支撐狹窄的冠脈,維持正常的血流而緩解癥狀,術(shù)后中期的效果比較滿意[12,16]。但是,支架治療術(shù)中及術(shù)后的并發(fā)癥則較多,如術(shù)中冠脈破裂和穿孔、支架斷裂、術(shù)后支架再狹窄等,而且對(duì)長(zhǎng)節(jié)段的心肌來(lái)說(shuō),支架治療也不合適[17-20]。外科治療重度心肌橋可取得良好的效果,而且并發(fā)癥少[21-24]。手術(shù)治療心肌橋主要有兩種方法。一是直接切開(kāi)心肌橋顯露冠狀動(dòng)脈,解除其受壓,但此類技術(shù)在心肌橋比較厚、長(zhǎng),冠脈比較深時(shí),手術(shù)難度大。因?yàn)榍虚_(kāi)時(shí)容易損傷冠脈,因此多需要在體外循環(huán)下進(jìn)行才能安全徹底,但這樣會(huì)增加患者的手術(shù)創(chuàng)傷。而且,如果患者年齡大,冠脈壁有粥樣硬化改變時(shí),即使切開(kāi)了心肌橋,手術(shù)也不能解除已形成的冠脈狹窄,所以這類手術(shù)多適用于年輕人、心肌橋短、冠脈較淺、心肌橋長(zhǎng)度不超過(guò)25 mm、深度不超過(guò)5 mm的患者[21,22]。而對(duì)于年齡比較大、心肌橋下冠脈有粥樣硬化性狹窄的患者,或心肌橋長(zhǎng)度過(guò)長(zhǎng)、較深時(shí),則主張行冠脈搭橋術(shù)以取得良好的效果[23,24]。本組病例平均年齡近63歲,加之前降支重度狹窄病變時(shí)間長(zhǎng),所以均采用了MIDCAB術(shù)進(jìn)行LIMA-LAD旁路移植手術(shù),使心肌橋遠(yuǎn)端心肌缺血得到了改善。術(shù)后中期隨訪,行LIMALAD的CT檢查,結(jié)果顯示所有橋血管均通暢良好,也充分說(shuō)明了LIMA-LAD遠(yuǎn)期效果的優(yōu)越性。雖有學(xué)者認(rèn)為[25],心肌橋患者行冠脈搭橋術(shù),術(shù)后競(jìng)爭(zhēng)性血流易致LAD阻塞,但這還沒(méi)有臨床依據(jù)證實(shí)。Sabik等[26]認(rèn)為,競(jìng)爭(zhēng)性血流可能會(huì)影響橋血管的遠(yuǎn)期通暢率,但對(duì)于重度冠脈狹窄來(lái)說(shuō),不會(huì)因?yàn)楦?jìng)爭(zhēng)性血流影響橋血管通暢率。本組患者均為重度狹窄,術(shù)后也沒(méi)有發(fā)現(xiàn)類似情況,心肌橋與非心肌橋兩組患者術(shù)后效果都一樣良好。
因此我們認(rèn)為,MIDCAB術(shù)進(jìn)行LIMA-LAD旁路移植是安全、有效的微創(chuàng)技術(shù),術(shù)后早期臨床效果好,遠(yuǎn)期吻合口通暢率高。MIDCAB治療心肌橋與非心肌橋性LAD病變都可以取得同樣的優(yōu)良效果。
[1]Kim PJ,Hur G,Kim SY,et al.Frequency of myocardial bridges and dynamic compression of epicardial coronary arteries:A comparison between computed tomography and invasive coronary angiography.Circulation,2009,119:1408-1416.
[2]Loukas M,Von Kriegenbergh K,Gilkes M,et al.Myocardial bridges:a review.Clin Anat,2011,24:675-683.
[3]Cakmak YO,Cavdar S,Yalin A,et al.Myocardial bridges of the coronary arteries in the human fetal heart.Anat Sci Int,2010,85:140-144.
[4]Molenkamp S,Hort W,Ge J,et al.Update on myocardial bridging.Circulation,2002,106:2616-2622.
[5]Bourassa MG,Butnaru A,Lesperance J,et al.Symptomatic my-ocardial bridges:Overview of ischemic mechanisms and currentdiagnostic and treatment strategies.J Am Coll Cardiol,2003,41:351-359.
[6]Feld H,Guadanino V,Hollander G,et al.Exercise-induced ventricular tachycardia in association with a myocardial bridge.Chest,1991,99:1295-1296.
[7]Kramer JR,Kitazume H,Proudfit WL,et al.Clinical significance of isolated coronary bridges:Benign and frequent condition involvingtheleftanteriordescendingartery.Am HeartJ,1982,103:283-288.
[8]熊龍根,陸東風(fēng),劉世明,等.冠狀動(dòng)脈造影時(shí)心肌橋的檢出率及其臨床意義.中國(guó)心血管病研究,2005,3:136-137.
[9]Tsujita K,Maehara A,Mintz GS,et al.Comparison of angiographic and intravascular ultrasonic detection of myocardial bridging of the left anterior descending coronary artery.Am J Cardiol,2008,102:1608-1613.
[10]Ural E,Bildirici U,Celikyurt U,et al.Long-term prognosis of non-interventionally followed patients with isolated myocardial bridge and severe systolic compression of the left anterior descending coronary artery.Clin Cardiol,2009,32:454-457.
[11]Ge J,Erbel R,Rupprecht HJ,et al.Comparison of intravascular ultrasound and angiography in the assessment of myocardial bridging.Circulation,1994,89:1725-1732.
[12]Klue HG,Schwarz ER,vom Dahl J,et al.Disturbed intracoronary hemodynamics in myocardial bridging:Early normalization by intracoronary stent placement.Circulation,1997,96:2905-2913.
[13]Ishii T,Asuwa N,Masuda S,et al.The effects of a myocardial bridge on coronary atherosclerosis and ischaemia.J Pathol,1998,185:4-9.
[14]王昌育,辛渭川,,廖菽丹,等.倍他樂(lè)克在急性心肌梗死中的應(yīng)用.中國(guó)心血管病研究,2006,4:798-799.
[15]李同社.冠狀動(dòng)脈心肌橋的臨床特點(diǎn)與治療.中國(guó)心血管病研究,2006,4:601-602.
[16]Prendergast BD,Kerr F,Starkey IR.Normalization of abnormal coronary fractionalflow reserve associated with myocardial bridging using an intracoronary stent.Heart,2000,83:705-707.
[17]Haager PK,Schwarz ER,vom Dahl J,et al.Long term angiographic and clinical follow up in patients with stent implantation for symptomatic myocardial bridging.Heart,2000,84:403-408.
[18]Berry JF,von Mering GO,Schmalfuss C,et al.Systolic compression of the left anterior descending coronary artery:A case series,review of the literature,and therapeutic options including stenting.Cathet Cardiovasc Interv,2002,56:58-63.
[19]Tandar A,Whisenant BK,Michaels AD.Stent fracture following stenting of a myocardial bridge:Report of two cases.Cathet Cardiovasc Interv,2008,71:191-196.
[20]Kursaklioglu H,Barcin C,Iyisoy A,et al.Angiographic restenosis after myocardial bridge stenting:A comparative study with direct stenting of de-novo atherosclerotic lesions.Jpn Heart J,2004,45:581-589.
[21]Downar J,Williams WG,McDonald C,et al.Outcome after“unroofing”of a myocardial bridge of the left anterior descending coronary artery in children with hypertrophic cardiomyopathy.Pediatr Cardiol,2004,25:390-393.
[22]Li W,Li Y,Sheng L,et al.Myocardial bridge:Is the risk of perforation increased?Can J Cardiol,2008,24:e80-81.
[23]Faruqui AMA,Maloy WC,F(xiàn)elner JM,et al.Symptomatic myocardial bridging of coronary artery.Am J Cardiol,1978,41:1305-1310.
[24]Parashara DK,Ledley GS,Kolter MN,et al.The combined presence of myocardial bridging and fixed coronary artery stenosis.Am Heart J,1993,125:1170-1172.
[25]Zou YX,Huang FJ,Wu Q,et al.Graft occlusion after coronary artery bypass grafting and stentdeformation and in-stent restenosis after succedent stenting in a patient with deep position myocardial bridging.Interact CardioVasc Thorac Surg,2012,15:537-539.
[26]Sabik JF 3rd,Lytle BW,Blackstone EH,et al.Does competitive flow reduce internal thoracic artery graft patency.Ann Thorac Surg,2003,76:1490-1496.
MIDCAB for the treatment of left anterior descending coronary artery lesions of myocardial bridge or non-myocardial bridge
JIANG Zhao-lei,MEI Ju,TANG Min,et al.Department of Cardiothoracic Surgery,Xinhua Hospital,Shanghai Jiaotong University School of Medicine,Shanghai 200092,China
MEI Ju,E-mail:ju_mei63@126.com
Objective To compare the clinical outcomes of minimally invasive direct coronary artery bypass(MIDCAB)for the treatment of left anterior descending coronary artery(LAD)lesions caused by myocardial bridge(MB)or non-myocardial bridge(non-MB).Methods From May 2006 to May 2013,37 patients underwent MIDCAB in our hospital.There were 8 female and 29 male.Patients aged 28 to 76 years old (average 62.9±6.8 years).The preoperative coronary angiography showed MB of significant LAD disease in 12 cases (MB GROUP),and non-MB of significant LAD disease in 25 cases(non-MB GROUP).All 37 patients were performed off-pump MIDCAB with LIMA to LAD grafting through a minimally invasive approach from left anterior fourth or fifth intercostal space with a 6 cm incision.Results All patients successfully underwent MIDCAB.No patient need to transit to conventional sternotomy.The time of operation ranged from 117 to 143 minutes.The postoperative ventilation time ranged from 4 to 6 hours.The length of ICU stay ranged from 22 to 45 hours.And the postoperative hospital stay ranged from 6 to 10 days.No patient need blood transfusion.There was no early death and significant complications related to acute myocardial infarction or stroke in perioperation.At a mean follow-up of (27.59±19.15)months,multislice spiral CT showed that the patency rate of LIMA to LAD grafting was 100%,and no patient had angina symptoms.There was no significant differences of perioperative data or follow-up outcomes between the twogroups(P>0.05).Conclusion MIDCAB can have similar and satisfactory results for the treatment of LAD lesions caused by MB or non-MB.
Coronary artery bypass grafting; Minimally invasive surgery; Myocardial bridge
國(guó)家臨床重點(diǎn)專科項(xiàng)目;上海市科學(xué)技術(shù)委員會(huì)資助項(xiàng)目(項(xiàng)目編號(hào):13XD1403200)
200092 上海市,上海交通大學(xué)醫(yī)學(xué)院附屬新華醫(yī)院心胸外科
梅舉,E-mail:ju_mei63@126.com
10.3969/j.issn.1672-5301.2014.03.001
R654.2
A
1672-5301(2014)03-0193-04
2013-12-25)